CMS Sticks To Its Original Thinking In Final VAD Coverage Decision
This article was originally published in The Gray Sheet
Executive Summary
The agency’s Oct. 31 national coverage determination for ventricular assist devices differs little from the August proposal – a result that analysts are speculating could benefit VAD maker Thoratec and potentially disadvantage HeartWare.